JP2008531470A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531470A5
JP2008531470A5 JP2007547106A JP2007547106A JP2008531470A5 JP 2008531470 A5 JP2008531470 A5 JP 2008531470A5 JP 2007547106 A JP2007547106 A JP 2007547106A JP 2007547106 A JP2007547106 A JP 2007547106A JP 2008531470 A5 JP2008531470 A5 JP 2008531470A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
phenyl
benzyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007547106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531470A (ja
JP4966202B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2005/001975 external-priority patent/WO2006066361A1/en
Publication of JP2008531470A publication Critical patent/JP2008531470A/ja
Publication of JP2008531470A5 publication Critical patent/JP2008531470A5/ja
Application granted granted Critical
Publication of JP4966202B2 publication Critical patent/JP4966202B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

JP2007547106A 2004-12-24 2005-12-23 治療または予防のための方法 Active JP4966202B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004907332 2004-12-24
AU2004907332A AU2004907332A0 (en) 2004-12-24 Method of Treatment or Prophylaxis
PCT/AU2005/001975 WO2006066361A1 (en) 2004-12-24 2005-12-23 Method of treatment or prophylaxis

Publications (3)

Publication Number Publication Date
JP2008531470A JP2008531470A (ja) 2008-08-14
JP2008531470A5 true JP2008531470A5 (enExample) 2008-12-25
JP4966202B2 JP4966202B2 (ja) 2012-07-04

Family

ID=36601295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007547106A Active JP4966202B2 (ja) 2004-12-24 2005-12-23 治療または予防のための方法

Country Status (16)

Country Link
US (5) US7795275B2 (enExample)
EP (3) EP2650011A1 (enExample)
JP (1) JP4966202B2 (enExample)
CN (3) CN102049048B (enExample)
CY (1) CY1114424T1 (enExample)
DK (1) DK1830869T3 (enExample)
ES (1) ES2425567T3 (enExample)
HR (1) HRP20130738T1 (enExample)
ME (1) ME01597B (enExample)
NZ (1) NZ555334A (enExample)
PL (1) PL1830869T3 (enExample)
PT (1) PT1830869E (enExample)
RS (1) RS52927B (enExample)
SI (1) SI1830869T1 (enExample)
WO (1) WO2006066361A1 (enExample)
ZA (3) ZA200704909B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2650011A1 (en) * 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
EP2952185A1 (en) * 2006-03-20 2015-12-09 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis of inflammatory pain
WO2008043087A2 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
CA2740389A1 (en) * 2008-10-15 2010-05-20 Gilead Sciences, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2787173C (en) * 2010-01-19 2018-05-01 Spinifex Pharmaceuticals Pty Ltd Methods and compositions for improved nerve conduction velocity
DE102010013075A1 (de) 2010-03-26 2011-09-29 B. Braun Melsungen Ag Antimikrobielle Wundauflage
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
DK2595960T3 (en) * 2010-07-21 2016-05-09 Novartis Ag Salt and solvates of a tetrahydroisoquinoline derivative
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
ES2969977T3 (es) 2011-08-23 2024-05-23 Libertas Bio Inc Compuestos de pirimido-piridazinona y uso de los mismos
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
PT2800738T (pt) 2012-01-06 2020-06-23 Novartis Ag Compostos heterocíclicos e métodos para a utilização dos mesmos
PT2807153T (pt) * 2012-01-25 2020-06-18 Novartis Ag Compostos heterocíclicos e métodos para seu uso
AU2013202978B2 (en) 2012-01-25 2016-05-19 Novartis Ag Heterocyclic compounds and methods for their use
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US9714224B2 (en) 2013-07-08 2017-07-25 Novartis Ag Heterocyclic compounds and methods of their use
EP4282272A3 (en) 2013-09-30 2024-01-24 FMC Corporation Method of delivering an agriculturally active ingredient
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
BR112016022062B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PL3122358T3 (pl) 2014-03-26 2021-06-14 Astex Therapeutics Ltd. Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
AR100936A1 (es) 2014-06-24 2016-11-09 Fmc Corp Formulaciones de espumas y concentrados emulsionables
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
PL3268356T3 (pl) 2015-03-12 2022-01-24 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
HRP20220012T1 (hr) 2015-09-23 2022-04-01 Janssen Pharmaceutica Nv Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
EP3393240A1 (en) 2015-12-23 2018-10-31 FMC Corporation In situ treatment of seed in furrow
US20190152918A1 (en) 2016-06-27 2019-05-23 Ratiopharm Gmbh Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
JP2019514862A (ja) 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
CA3060316A1 (en) 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
WO2018224037A1 (zh) * 2017-06-09 2018-12-13 南京明德新药研发股份有限公司 作为at2r受体拮抗剂的羧酸衍生物
GB201710906D0 (en) * 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
CN111902401B (zh) * 2018-02-23 2023-06-13 北京泰德制药股份有限公司 受体抑制剂、包含其的药物组合物及其用途
CA3094001C (en) 2018-03-23 2024-01-23 Beijing Tide Pharmaceutical Co., Ltd. Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
US20210238229A1 (en) * 2018-06-14 2021-08-05 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
PE20241304A1 (es) 2021-07-30 2024-06-24 Confo Therapeutics N V Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o senalizacion mediada por at2r
JP2025521119A (ja) 2022-05-17 2025-07-08 イーライ リリー アンド カンパニー Ａｔ２ｒアンタゴニスト及びその使用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531485A (en) * 1967-08-14 1970-09-29 American Home Prod Aryl-substituted diazabicycloalkanes
US3957795A (en) * 1974-01-28 1976-05-18 Delmar Chemicals Limited Novel cyclopentene and cyclopentane derivatives
US3975795A (en) 1975-01-20 1976-08-24 Union Carbide Corporation Product stuffing apparatus and method
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US5091390A (en) 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
JP3208139B2 (ja) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
US5385894A (en) 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
WO1992020661A1 (en) 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9208116D0 (en) 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
NZ251741A (en) 1992-04-13 1997-06-24 Zeneca Ltd Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
AU685767B2 (en) * 1992-12-11 1998-01-29 Novartis Ag Substituted benzazepinones
US5395844A (en) 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
AP9400651A0 (en) 1993-07-15 1995-12-30 Pfizer Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists.
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
US5610165A (en) 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
FR2739625B1 (fr) 1995-10-09 1997-12-05 Atochem Elf Sa Copolymeres hydrosolubles associatifs triblocs
GB2323783A (en) 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
US6277839B1 (en) 1998-10-07 2001-08-21 Merck Frosst Canada & Co. Biphenylene lactams as prostaglandin receptor ligands
RU2271809C2 (ru) * 1998-12-23 2006-03-20 Новартис Аг Применение антагониста рецептора at-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
AU2092601A (en) * 1999-12-15 2001-06-25 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001043761A2 (en) 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
AU2001282886A1 (en) 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
WO2002040008A2 (en) 2000-11-17 2002-05-23 Warner-Lambert Company Llc Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
EG23054A (en) 2001-01-22 2004-02-29 Sankyo Co Pyrrole derivatives their preparation and their therapeutic uses
WO2002060439A1 (en) * 2001-01-29 2002-08-08 Takeda Chemical Industries, Ltd. Analgesic and antiinflammatory drugs
US20030170222A1 (en) 2001-01-29 2003-09-11 University Of Utah Research Foundation Beta-superfamily conotoxins
CA2470567A1 (en) * 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
WO2003064414A1 (en) 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
AR038377A1 (es) 2002-02-08 2005-01-12 Merck & Co Inc Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)
WO2003077912A1 (en) * 2002-03-20 2003-09-25 The University Of Queensland Method of treatment and/or prophylaxis
US7348348B2 (en) 2002-04-30 2008-03-25 Merck & Co. Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
CA2486302A1 (en) 2002-05-17 2003-11-27 Faust Pharmaceuticals Methods for the prevention and/or the treatment of neurological disorders
WO2003101381A2 (en) 2002-05-29 2003-12-11 Merck & Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
WO2004006959A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
WO2004099248A2 (en) 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
EP2650011A1 (en) 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin

Similar Documents

Publication Publication Date Title
JP2008531470A5 (enExample)
US10307463B2 (en) Method for administering omega-conopeptide
Sethi et al. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo
KR102122941B1 (ko) 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
US20080159980A1 (en) Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy
Sasaki et al. Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys
TR201906789T4 (tr) Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
US20250235544A1 (en) Tripartite Modulators of Endosomal G Protein-Coupled Receptors
CA2115828A1 (en) Calcium receptor active molecules
US11154587B2 (en) Use of peptides to stimulate the immune system
Cahalan et al. Sphingosine 1-phosphate receptor 1 (S1P1) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P1 antagonist
EP3881859A1 (en) Methods and compositions for increasing neurogenesis and angiogenesis
JP2006501165A5 (enExample)
JP2018526440A (ja) 免疫系を刺激するためのインドール化合物の使用
ES3035910T3 (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
US20060241037A1 (en) Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
Meini et al. Characterization of bradykinin B2 receptor antagonists in human and rat urinary bladder
AU2016205030A1 (en) Restoring physiology in iron-deficient organisms using small molecules
US20120022129A1 (en) Targeting of Histone Deacetylase 2, Protein Kinase CK2, and Nuclear Factor NRF2 For Treatment of Inflammatory Diseases
JP2024501800A (ja) 筋ジストロフィーを治療するためのエクソンスキッピングオリゴヌクレオチドコンジュゲートを含む組成物
EP3596477B1 (en) Method for creating a renal injury model to screen molecules for the treatment of renal injury
Dunlop et al. Sulphur-containing excitatory amino acid-evoked Ca2+-independent release of D-[3H] aspartate from cultured cerebellar granule cells: The role of glutamate receptor activation coupled to reversal of the acidic amino acid plasma membrane carrier
Frenguelli et al. Electrogenic uptake contributes a major component of the depolarizing action of l‐glutamate in rat hippocampal slices
US20240325747A1 (en) Compositions and methods of a concomitant therapy of alternating electric fields and n-cadherin inhibitor
US20230142111A1 (en) Compositions and methods for the treatment of pervasive development disorders